APA (7th ed.) Citation

AS, J., MLH, H., AS, M., KL, O., C, D., RL, O., . . . AC, K. (2026). Chronic complication risk and benefits of fenofibrate in type 2 diabetes by a PPARα polymorphism (rs6008845, C/T): A FIELD trial substudy. Diabetes research and clinical practice, 234, 113168. https://doi.org/10.1016/j.diabres.2026.113168

Chicago Style (17th ed.) Citation

AS, Januszewski, et al. "Chronic Complication Risk and Benefits of Fenofibrate in Type 2 Diabetes by a PPARα Polymorphism (rs6008845, C/T): A FIELD Trial Substudy." Diabetes Research and Clinical Practice 234 (2026): 113168. https://doi.org/10.1016/j.diabres.2026.113168.

MLA (9th ed.) Citation

AS, Januszewski, et al. "Chronic Complication Risk and Benefits of Fenofibrate in Type 2 Diabetes by a PPARα Polymorphism (rs6008845, C/T): A FIELD Trial Substudy." Diabetes Research and Clinical Practice, vol. 234, 2026, p. 113168, https://doi.org/10.1016/j.diabres.2026.113168.